 |
|
|
||||||||||||||
 |
|
|
One simple test could change the future
The test is intended for use by physicians as an aid in management of patients considered to be at risk for Type 2 diabetes.
The PreDx™ Diabetes Risk Test is performed using a routine fasting blood sample. It quantifies a panel of biomarkers, resulting in a single score: the PreDx™ Diabetes Risk Score. The biomarkers used in the PreDx Diabetes Risk Test were selected by testing baseline samples from individuals 30 to 60 years of age who developed diabetes within 5 years and a random selection of controls from the same population.1-3 Using mathematical modeling, the PreDx Diabetes Risk Test combines multiple biomarkers into a single diabetes risk factor between 1 (least risk) and 10 (highest risk).2
NOTE: The PreDx Diabetes Risk Test is an adjunctive test to complement, not replace, other diagnostic and clinical procedures.
The PreDx™ Diabetes Risk Score may be used as a motivational tool in helping to increase patient compliance for those at high risk.
*Performed exclusively by the Tethys Clinical Laboratory
1. Population description: Jørgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. European Journal of Cardiovascular Prevention and Rehabilitation 2003;10:377-386.
2. Data on file, Tethys Clinical Laboratory, Tethys Bioscience, Inc., 2008
3. Kolberg J, Gerwien R, Moler E, Rowe M, Urdea M, McKenna M, Hansen T, Pedersen O, Jørgensen T. Training and validation of a multimarker algorithm for the prediction of Type 2 diabetes from a 5 yr prospective study of 6,784 Danish people (Inter99). American Diabetes Association 68th Scientific Sessions, 2008.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)
Sep 24, 2009
A preemptive strike on diabetes: Emeryville's Tethys Biosciences rolls out pre-diabetes test
Tethys Bioscience featured in the September/October 2009 issue of Healthcare Journal of Northern California.
Aug 31, 2009
Personnel Additions and Promotions at Tethys Bioscience
Management Team in Position for Full Commercialization of its Line of Personalized-Prevention Diagnostics
Jul 15, 2009
Peer-Reviewed Publications Demonstrate Tethys Bioscience's Ability to Identify those at Highest Risk of Developing Type 2 Diabetes within Five Years
Diabetes journals publish two definitive papers supporting both the science behind and the clinical performance of lead product, the PreDx™ Diabetes Risk Score (DRS)
Jun 7, 2009
New Data in Support of Tethys Bioscience's PreDx™ Diabetes Risk Score Presented at ADA Scientific Sessions
New data support cost-effectiveness and clinical utility of a risk assessment test for type 2 diabetes